|
what is nonalcoholic fatty liver diseasee, seronegative, saturated and unsaturated fatty acids , alcohol/addiction/illegaldrugs news, weight loss, menstrual disorders, symptoms of nonalcoholic fatty liver diseasee, plump jack squaw valley , symptoms of fatty liver , hepatitis c virus, cocaine, liver disease treatment, hepatitis c treatment, fatty woman , varices, fatty girl lyrics , fattyliver disease becoming popular, hepatitis c, galactosemia, plump rumps , plump rumps tgp ,
|
Links Nonalcoholic ribaveron fatty liver disease: ribaveron From steatosis to cirrhosis.Farrell GC, Larter CZ.The Storr Liver Unit, Westmead's Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia.Nonalcoholic steatohepatitis (NASH), the lynchpin between steatosis and cirrhosis in the spectrum of nonalcoholic fatty liver disorders (NAFLD), was barely recognized in 1981. NAFLD is now present in 17% to 33% of Americans, has a worldwide distribution, and parallels the frequency of central adiposity, obesity, insulin ribaveron resistance, metabolic syndrome and type 2 diabetes. NASH could be present in one third of NAFLD cases. Age, activity of steatohepatitis, and established fibrosis predispose to cirrhosis, which has a 7- to 10-year liver-related mortality of 12% to 25%. Many cases of cryptogenic cirrhosis are likely endstage NASH. While endstage NAFLD currently accounts for 4% to 10% of liver transplants, this may soon rise. Pathogenic concepts for NAFLD/NASH must account for the strong links with overnutrition and underactivity, insulin resistance, and genetic factors.
|
